Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJM, Sekijima Y, et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid 2018;25(4):215-9.
Papa R, Lachmann HJ. Secondary, AA, Amyloidosis. Rheum Dis Clin N Am 2018;44(4):585-03.
Brunger AF, Nienhuis HLA, Bijzet J, Hazenberg BPC. Causes of AA amyloidosis: a systematic review. Amyloid 2020;27(1):1-12.
Dhillon V, Woo P, Isenberg D. Amyloidosis in the rheumatic diseases. Ann Rheum Dis 1989;48(8):696-01.
Obici L, Raimondi S, Lavatelli F, Bellotti V, Merlini G. Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum 2009;61(10):1435-40.
Horak P, Smrzova A, Krejci K, Tichy T, Zadrazil J, Skacelova M. Renal manifestations of rheumatic diseases. A review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2013;157(2):98-104.
Cytawa W, Teodorczyk J, Lass P. Nuclear imaging of amyloidosis. Pol J Radiol 2014;79:222-7.
Nienhuis HL, Bijzet J, Hazenberg BP. The prevalence and management of systemic amyloidosis in Western countries. Kidney Dis (Basel, Switzerland) 2016;2(1):10-9.
Obici L, Merlini G. AA amyloidosis: basic knowledge, unmet needs and future treatments. Swiss Med Wkly 2012;142:13580.
Real de Asúa D, Costa R, Galván JM, Filigheddu MT, Trujillo D, Cadiñanos J. Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol 2014;6:369-77.
Talbott JH, Terplan KL. The kidney in gout. Medicine (Baltimore). 1960;39:405-67.
Talbott JH. Gout. 3rd ed. New York: Grune and Stratton 1967:95-6.
Levo Y, Shalev O, Rosenmann E, Eliakim M. Gout and amyloidosis. Ann Rheum Dis 1980;39:589-91.
Rubinow A, Sonnemblick M. Amyloidosis secondary to polyarticular gout. Arthritis Rheum 1981;24:1425-27.
Lens XM, Roselló R, Montoliu J, Solé M, Darnell A, Rotés J, et al. Amyloidosis secondary to gout. J Rheumatol 1985;12:1024-6.
Jacobelli S, Vial S, Rosenberg H, Benson MD, Scheinberg MA. Amyloidosis secondary to gout. Identification with a monoclonal antibody to amyloid protein A. Clin Rheumatol 1988;7:534-37.
Gumá M, Bayés B, Bonet J, Olivé A. Gout and secondary amyloid. Clin Rheumatol 1999;18:54-55.
Vernerová Z, Rychlík I, Brunerová L, Dvořáková L, Pavelková A, Šebesta I. An unusual cause of renal amyloidosis secondary to gout: the first description of familial occurrence. Nucleosides Nucleotides Nucleic Acids 2006;25:1305-08.
Ter Borg EJ, Wegewijs MA, de Bruin P. Gout and AA Amyloidosis A Case Report and Review of the Literature. JCR 2017;23(4):233-4.
Brunger AF, Nienhuis HLA, van Rheenen RWJ, Korte MR, Bijzet J, Gans ROB, et al. Obesity-induced AA amyloidosis: A diagnosis of exclusion Int J Clin Rheumatol 2020;15(2):26-2.
Cantarini L, Rigante D, Brizi MG, Lucherini OM, Sebastiani GD, Vitale A, et al. Clinical and biochemical landmarks in systemic autoinflammatory diseases. Ann Med 2012;44(7):664-73.
Steiger S, Harper JL. Mechanisms of spontaneous resolution of acute gouty inflammation. Curr Rheumatol Rep 2014;16(1):392.
Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440(7081):237-41.
Amaral FA, Costa VV, Tavares LD, Sachs D, Coelho FM, Fagundes CT, et al. NLRP3 inflammasome-mediated neutrophil recruitment and hypernociception depend on leukotriene B(4) in a murine model of gout Arthritis Rheum 2012;64(2):474-84.
Busso N, Ea HK. The mechanisms of inflammation in gout and pseudogout (CPP-induced arthritis). Reumatismo 2012;63(4):230-7.
Tavares LD, Galvão I, Costa VV, Batista NV, Rossi LCR, Brito CB, et al. Phosphoinositide-3 kinase gamma regulates caspase-1 activation and leukocyte recruitment in acute murine gout. J Leukoc Biol 2019;106(3):619-29.
Bousoik E, Qadri M, Elsaid KA. CD44 Receptor Mediates Urate Crystal Phagocytosis by Macrophages and Regulates Inflammation in A Murine Peritoneal Model of Acute Gout. Sci Rep 2020;10(1):5748.
Galvão I, de Carvalho RVH, Vago JP, Silva ALN, Carvalho TG, Antunes MM, et al. The role of annexin A1 in the modulation of the NLRP3 inflammasome. Immunology. 2020;160(1):78-89.
Mitroulis I, Kambas K, Ritis K. Neutrophils, IL-1β, and gout: is there a link? Semin Immunopathol 2013;35(4):501-12.
Blank N, Hegenbart U, Schönland S. Causes and treatment of systemic amyloidosis. Zeitschrift für Rheumatologie 2016;75(2):141-50.
Shtrasburg S, Pras M, Gal R, Salai M, Livneh A. Inhibition of the second phase of amyloidogenesis in a mouse model by a single-dose colchicine regimen. J Lab Clin Med 2001;138:107-11.
Keizman IK, Greenwald M, Ravid M. Colchicine inhibition of the first phase of amyloid synthesis in experimental animals. Br J Exp Pathol 1976;57:686-8.
Unverdi S, Inal S, Ceri M, Unverdi H, Batgi H, Tuna R, et al. Is colchicine therapy effective in all patients with secondary amyloidosis? Ren Fail 2013;35(8):1071-4.
Dasgeb B, Kornreich D, McGuinn K, Okon L, Brownell I, Sackett DL. Colchicine: an ancient drug with novel applications. Br J Dermatol 2018;178(2):350-6.
Burger D, Dayer JM, Palmer G, Gabay C. Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract Res Clin Rheumatol 2006;20(5):879-96.
Westermark GT, Fändrich M, Westermark P. AA amyloidosis: pathogenesis and targeted therapy. Annu Rev Pathol Mech Dis 2015;10(1):321-44.
Lane T, Wechalekar AD, Gillmore JD, Hawkins PN, Lachmann HJ. Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiology. Amyloid 2017;24(3):189-93.
Schlesinger N, MeulemeesterMD, Pikhlak A, Yücel AE, Richard D, Murphy V, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study Arthritis Res Ther 2011;13(2):R53.
Schlesinger N, Mysler E, Lin HY, De Meulemeester M, Rovensky J, Arulmani U, et al. A. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study Ann Rheum Dis 2011;70(7):1264-71.
Varan Ö, Kucuk H, Babaoglu H, Guven SC, Ozturk MA, Haznedaroglu S, et al. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis. Mod Rheumatol 2019;29(2):363-6.
Trabulus S, Korkmaz M, Kaya E, Seyahi N. Canakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever. Clin Transplant 2018;32(8):e13345.
Mariotte A, De Cauwer A, Po C, Abou-Faycal C, Pichot A, Paul N, et al. A mouse model of MSU-induced acute inflammation in vivo suggests imiquimod-dependent targeting of Il-1β as relevant therapy for gout patients. Theranostics 2020;10(5):2158-71.